Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

Summary

The primary objective of the study is to determine the effect of rimonabant 20 mg daily when added to ongoing metformin therapy on glycemic control (HbA1c) over a 36 week period in patients with type 2 diabetes. Secondary objectives include evaluation of other markers of glycemic control, lipid profile, body weight, and abdominal obesity. Also, the trial will study the safety of rimonabant when added to metformin over a period of 47 weeks.

Timeline

Start

2008-05

Primary completion

2009-02

Completion

2009-02

Outcome

Outcome not reported

Stopped: “Company decision taken in light of demands by certain national health authorities”

Drugs

Indications